Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 2
2012 2
2013 4
2014 6
2015 5
2016 6
2017 8
2018 9
2019 8
2020 5
2021 6
2022 8
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Intrarenal Renin-Angiotensin System Activation Alters Relationship Between Systolic Blood Pressure and Progression of Chronic Kidney Disease.
Park CH, Kim HW, Park JT, Chang TI, Yoo TH, Lee J, Sung S, Jung JY, Hyun YY, Oh KH, Kang SW, Han SH; on the behalf of the KNOW-CKD (Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators. Park CH, et al. Among authors: hyun yy. Hypertension. 2023 May;80(5):1024-1034. doi: 10.1161/HYPERTENSIONAHA.122.20824. Epub 2023 Mar 28. Hypertension. 2023. PMID: 37075134
Solitary kidney and risk of chronic kidney disease.
Kim S, Chang Y, Lee YR, Jung HS, Hyun YY, Lee KB, Joo KJ, Yun KE, Shin H, Ryu S. Kim S, et al. Among authors: hyun yy. Eur J Epidemiol. 2019 Sep;34(9):879-888. doi: 10.1007/s10654-019-00520-7. Epub 2019 Apr 25. Eur J Epidemiol. 2019. PMID: 31025238
Coronary Artery Calcification Score and the Progression of Chronic Kidney Disease.
Yun HR, Joo YS, Kim HW, Park JT, Chang TI, Son NH, Yoo TH, Kang SW, Sung S, Lee KB, Lee J, Oh KH, Han SH; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) investigators; KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Yun HR, et al. J Am Soc Nephrol. 2022 Aug;33(8):1590-1601. doi: 10.1681/ASN.2022010080. Epub 2022 Jun 2. J Am Soc Nephrol. 2022. PMID: 35654602 Free PMC article.
Inhibition of Renal Stellate Cell Activation Reduces Renal Fibrosis.
Cha JJ, Mandal C, Ghee JY, Yoo JA, Lee MJ, Kang YS, Hyun YY, Lee JE, Kim HW, Han SY, Han JY, Chung AY, Yoon DW, Rhyu IJ, Oh J, Cha DR. Cha JJ, et al. Among authors: hyun yy. Biomedicines. 2020 Oct 19;8(10):431. doi: 10.3390/biomedicines8100431. Biomedicines. 2020. PMID: 33086608 Free PMC article.
82 results